Exelixis' Strong Cabometyx Start Signals Changing Of Guard In Kidney Cancer Market
One of a trio of new drugs shaking up the kidney cancer market, Cabometyx (cabozantinib) does better than expected in its first nine weeks on the US market, and additional indications are on the near horizon.
You may also be interested in...
Latest set of oncology clinical practice guidelines issued in September highlight Cabometyx as preferred treatment option.
Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.
As the RCC field braces for another paradigm change, early studies combining tyrosine kinase inhibitors with PD-1/L1 inhibitors suggest the highest response rates are found with Inlyta (axitinib) as a partner.